- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.07. | Dicot Pharma AB: Dicot Pharma recruits Cecilia Driving as new Chief Financial Officer | 159 | GlobeNewswire (Europe) | Uppsala, Sweden, July 1, 2026. Dicot Pharma AB announces that Cecilia Driving has been appointed as new Chief Financial Officer (CFO). She will take up the position on September 1, succeeding Björn... ► Artikel lesen | |
| DICOT PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.06. | New equity right for trading, Dicot Pharma AB | 331 | GlobeNewswire | At the request of Dicot Pharma AB, equity rights will be traded on First North Growth Market as from 01 July 2026.
Security name:
DICOT PHARMA AB TO7
Short name:
DICOT... ► Artikel lesen | |
| 25.06. | Dicot Pharma AB: Dicot Pharma receives FDA clearance to initiate the first part of the Phase 2b study with LIB-01 in the U.S. | 854 | GlobeNewswire (Europe) | Uppsala, Sweden, June 25, 2026. Dicot Pharma AB announces that the company has received clearance from the U.S. Food and Drug Administration (FDA) to initiate the first part (Part I) of the Phase 2b... ► Artikel lesen | |
| 23.06. | New last trading day for paid subscription units (BTU) of Dicot Pharma AB | 217 | GlobeNewswire | At the request of Dicot Pharma AB, the last trading day in Dicot Pharma AB's paid subscription units will be changed from 2026-06-24 to 2026-06-25.
Instrument:
Paid subscription units
Short... ► Artikel lesen | |
| 09.06. | Dicot Pharma AB: Dicot Pharma announces final outcome in the oversubscribed rights issue and carries out directed share issues | 580 | GlobeNewswire (Europe) | Uppsala, Sweden, June 9, 2026. Dicot Pharma AB announced on June 4, 2026, the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue"). Today, the company... ► Artikel lesen | |
| 04.06. | Dicot Pharma AB: Dicot Pharma announces preliminary outcome in oversubscribed rights issue | 406 | GlobeNewswire (Europe) | Uppsala, Sweden, June 4, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") today announces the preliminary outcome of the rights issue of units of approximately SEK 210 million (the "Rights Issue")... ► Artikel lesen | |
| 03.06. | Decision by the Disciplinary Committee regarding Dicot Pharma AB | 215 | GlobeNewswire | Stockholm, June 3, 2026 The Disciplinary Committee of Nasdaq Stockholm has found that Dicot Pharma AB (the "Company") has not breached the rules of Nasdaq Stockholm (the "Rulebook") and has therefore... ► Artikel lesen | |
| 01.06. | Dicot Pharma AB: Dicot Pharma receives patent approval in Japan for LIB-01 | 179 | GlobeNewswire (Europe) | Uppsala, Sweden, June 1, 2026. Dicot Pharma has been granted a new patent in Japan for the active substance in LIB-01. The patent strengthens the intellectual property of the company's drug candidate... ► Artikel lesen | |
| 29.05. | Dicot Pharma AB: Dicot Pharma announces the final subscription date for units in the ongoing rights issue | 416 | GlobeNewswire (Europe) | Uppsala, Sweden, May 29, 2026. Thursday, June 4, 2026, is the final day for subscription in Dicot Pharma AB's ("Dicot Pharma" or "the Company") ongoing rights issue of units, consisting of shares and... ► Artikel lesen | |
| 27.05. | Dicot Pharma AB: Dicot Pharma receives indications of interest for approx. SEK 15.6 million from existing shareholders in the ongoing rights issue | 352 | GlobeNewswire (Europe) | Uppsala, Sweden, May 27, 2026. Dicot Pharma AB ("Dicot Pharma" or the "Company") has now received indications of interest from certain major shareholders totaling approximately SEK 15.6 million in the... ► Artikel lesen | |
| 20.05. | Dicot Pharma AB: Dicot Pharma completes tablet manufacturing ahead of phase 2b clinical study | 322 | GlobeNewswire (Europe) | Uppsala, Sweden, May 20, 2026. Dicot Pharma AB announces that the company has successfully completed manufacturing of the drug candidate LIB-01 as a tablet for the planned phase 2b study, which is intended... ► Artikel lesen | |
| 19.05. | Dicot Pharma AB: Dicot Pharma publishes prospectus in connection with the forthcoming rights issue | 321 | GlobeNewswire (Europe) | Dicot Pharma AB ("Dicot Pharma" or the "Company") today, on May 19, 2026, publishes an EU Follow-on Prospectus (the "Prospectus") in connection with the rights issue of units, consisting of shares and... ► Artikel lesen | |
| 08.05. | Dicot Pharma AB: Dicot Pharma has resolved on an 80% guaranteed rights issue of approximately SEK 210 million | 952 | GlobeNewswire (Europe) | Uppsala, Sweden, May 8, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") announced on April 28, 2026 its intention to resolve on a rights issue with preferential rights... ► Artikel lesen | |
| 06.05. | Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma | 291 | GlobeNewswire (Europe) | Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.
Annual report and resultsThe meeting adopted the income statements... ► Artikel lesen | |
| 30.04. | Dicot Pharma AB: Dicot Pharma presents interim report Q1 2026 and invites to a webcast | 299 | GlobeNewswire (Europe) | Uppsala, Sweden, April 30, 2026. Dicot Pharma AB publishes its interim report for the first quarter of 2026. The report is available as an attached document and on www.dicotpharma.com. The company will... ► Artikel lesen | |
| 28.04. | Dicot Pharma AB: Dicot Pharma intends to carry out an 80% already secured rights issue of SEK 210 million | 682 | GlobeNewswire (Europe) | Uppsala, Sweden, April 28, 2026. The Board of Directors of Dicot Pharma AB ("Dicot Pharma" or the "Company") intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding... ► Artikel lesen | |
| 12.03. | Dicot Pharma AB: Dicot Pharma initiates tablet manufacturing ahead of phase 2b clinical study | 395 | GlobeNewswire (Europe) | Uppsala, Sweden, March 12, 2026. Dicot Pharma AB announces that the company has successfully completed the development of LIB-01 as a tablet and initiated manufacturing of tablets ahead of the upcoming... ► Artikel lesen | |
| 18.12.25 | Dicot Pharma AB: Dicot Pharma signs agreement with CRO ahead of phase 2b study with LIB-01 | 560 | GlobeNewswire (Europe) | Uppsala, Sweden, December 18, 2025. Dicot Pharma AB has signed an agreement with a global contract research organization (CRO) to prepare for the planned phase 2b clinical study of the drug candidate... ► Artikel lesen | |
| 23.10.25 | Dicot Pharma AB: Dicot Pharma Announces Positive Results from its Phase 2a Study | 574 | GlobeNewswire (Europe) | Uppsala, Sweden October 23, 2025. Today, Dicot Pharma announces positive topline results from its phase 2a study of LIB-01 for the treatment of erectile dysfunction. The outcomes demonstrated clinically... ► Artikel lesen | |
| 27.08.25 | Dicot Pharma AB: Dicot Pharma included in global stock index | 471 | GlobeNewswire (Europe) | Uppsala, Sweden, August 27, 2025. As of today, the Swedish, erectile dysfunction drug developer Dicot Pharma has been incorporated into the MSCI Global Micro Cap Index, managed by MSCI, the world's... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 134,25 | -0,70 % | Merck investiert in neues Prüfzentrum für Europa | DARMSTADT (dpa-AFX) - Der Pharma- und Technologiekonzern Merck KGaA hat an seinem Hauptsitz Darmstadt ein neues Prüfzentrum für die Freigabe von Arzneimitteln eröffnet. Die Investition beziffert das... ► Artikel lesen | |
| BAYER | 47,620 | +0,32 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| CHINA PHARMA HOLDINGS | 8,640 | +738,84 % | China Pharma: Keine Erklärung für ungewöhnliche Handelsaktivitäten | ||
| NOVO NORDISK | 43,495 | +0,07 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| ZHENGYE BIOTECHNOLOGY | 2,840 | -64,54 % | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 43,190 | +5,16 % | Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? | ||
| AQUESTIVE THERAPEUTICS | 4,040 | +2,41 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| PFIZER | 21,850 | +0,78 % | BioNTech und Pfizer werden zum geopolitischen Pharmafall | Die gemeinsame Entwicklung des Corona-Impfstoffs galt als Musterbeispiel globaler Arbeitsteilung: deutsche mRNA-Forschung, amerikanische Pharmakapazitäten, internationale Produktion und staatlich organisierte... ► Artikel lesen | |
| ELI LILLY | 1.025,00 | +2,05 % | Novo Nordisk, Eli Lilly und GSK investieren Milliarden - warum Biotech plötzlich wieder zum Übernahmekandidaten wird | ||
| GSK | 22,210 | -1,33 % | GSK zieht bei Camlipixant die Reißleine, doch der Fokus der Anleger liegt ohnehin auf anderen Bereichen | Die GSK-Aktie segelt schon seit einer Weile auf hohem Niveau seitwärts und Ausbruchsversuche sind schon seit Monaten nicht mehr zu beobachten. Die Anleger warten darauf, dass es endlich Anzeichen für... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 77,68 | +4,11 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| NOVARTIS | 135,04 | +2,90 % | Neuer Meilenstein: FDA-Entscheidung sorgt für Hoffnung: Novartis gelingt Durchbruch | © Foto: Spencer Jones - picture alliance / Glasshouse ImagesDie FDA hat Fabhalta von Novartis vollständig zugelassen. Das Medikament verlangsamt den Verlust der Nierenfunktion bei einer schweren Autoimmunerkrankung.Novartis... ► Artikel lesen | |
| SCHOTT PHARMA | 20,350 | -1,69 % | Aktien KW 29 Iran-Krieg 2.0, KI-Sorgen, da hilft auch keine Zinshoffnung. TACO ist gefordert! News. Rheinmetall. Siemens Energy. Pyramid. Schott Pharma. Nordex. 123Fahrschule. LAIQON. Mutares. SFC Energy. Kontron. MHP Hotel. Bastei Lübbe. Wacker Neuson. C | Aktien - und der Traum von neuen Börsenrekorden ist erstmal ausgeträumt. Solange am Persischen Golf nicht ein dauerhafter Waffenstillstand, besser noch Friedensschluss kommt, sind die Aktienmärkte im... ► Artikel lesen | |
| DERMAPHARM | 41,600 | -2,23 % | Finanzaufsicht Bafin untersucht Jahresabschluss von Dermapharm | FRANKFURT (dpa-AFX) - Die Finanzaufsicht Bafin hat eine Prüfung des Jahresabschlusses und des Lageberichts des Arzneimittelherstellers Dermapharm für das Jahr 2025 eingeleitet. Es lägen konkrete Anhaltspunkte... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 14,390 | +5,96 % | Cathie Wood Effekt beflügelt Biotech: Startet jetzt die Mega-Rallye bei dieser klinischen Wachstumsperle? |
DICOT PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,016 Euro und damit +3,85 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DICOT PHARMA AB finden Sie auf Wallstreet Online.